Abstract:Mycobacterium tuberculosis (Mtb), the pathogen responsible for tuberculosis (TB), is the leading cause of bacterial disease-related death worldwide. Current antibiotic regimens for the treatment of TB remain dated and suffer from long treatment times as well as the development of drug resistance. As such, the search for novel chemical modalities that have selective or potent anti-Mtb properties remains an urgent priority, particularly against multidrug-resistant (MDR) Mtb strains. Herein, we design and synthesize 35 novel benzo[c]phenanthridine derivatives (BPDs). The two most potent compounds, BPD-6 and BPD-9, accumulated within the bacterial cell and exhibited strong inhibitory activity (MIC90 ~2 to 10 µM) against multiple Mycobacterium strains while remaining inactive against a range of other Gram-negative and Gram-positive bacteria. BPD-6 and BPD-9 were also effective in reducing Mtb survival within infected macrophages, and BPD-9 reduced the burden of Mycobacterium bovis BCG in the lungs of infected mice. The two BPD compounds displayed comparable efficacy to rifampicin (RIF) against non-replicating Mtb (NR-Mtb). Importantly, BPD-6 and BPD-9 inhibited the growth of multiple MDR Mtb clinical isolates. Generation of BPD-9-resistant mutants identified the involvement of the Mmr efflux pump as an indirect resistance mechanism. The unique specificity of BPDs to Mycobacterium spp. and their efficacy against MDR Mtb isolates suggest a potential novel mechanism of action. The discovery of BPDs provides novel chemical scaffolds for anti-TB drug discovery.IMPORTANCEThe emergence of drug-resistant tuberculosis (TB) is a serious global health threat. There remains an urgent need to discover new antibiotics with unique mechanisms of action that are effective against drug-resistant Mycobacterium tuberculosis (Mtb). This study shows that novel semi-synthetic compounds can be derived from natural compounds to produce potent activity against Mtb. Importantly, the identified compounds have narrow spectrum activity against Mycobacterium species, including clinical multidrug-resistant (MDR) strains, are effective in infected macrophages and against non-replicating Mtb (NR-Mtb), and show anti-mycobacterial activity in mice. These new compounds provide promising chemical scaffolds to develop potent anti-Mtb drugs of the future.

Proteomic Characterization of Mycobacterium Tuberculosis Reveals Potential Targets of Bostrycin.

Identification of Bostrycin Derivatives As Potential Inhibitors of Mycobacterium Tuberculosis Protein Tyrosine Phosphatase (Mptpb)

Antituberculotic Activity of Bostrycin and Its Influence on Bacterial Gene Expressions

In Vitro Activity of Tetracycline Analogs against Multidrug-resistant and Extensive drug resistance Clinical Isolates of Mycobacterium tuberculosis

Deletion of the Mycobacterium tuberculosis cyp138 gene leads to changes in membrane-related lipid composition and antibiotic susceptibility

Inhibition of Mycobacterium tuberculosis MtrA response regulator by anticancer drugs via computational methods

Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates

Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system

Repurposing an Antioxidant to Kill <i>Mycobacterium tuberculosis</i> by Targeting the 50S Subunit of the Ribosome

Identification of gene targets that potentiate the action of rifampicin on Mycobacterium bovis BCG

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Nonsteroidal Anti-Inflammatory Drug Sensitizes Mycobacterium Tuberculosis To Endogenous And Exogenous Antimicrobials

Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis.

Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant Mycobacterium tuberculosis

Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis

Target Prediction for an Open Access Set of Compounds Active Against Mycobacterium Tuberculosis

An Extensive Computational Investigation of Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors from Diverse‐Lib Compounds Library

Structure of the<i>Mycobacterium tuberculosis</i>proteasome and mechanism of inhibition by a peptidyl boronate

Overcoming Mycobacterium Tuberculosis Through Small Molecule Inhibitors to Break Down Cell Wall Synthesis

Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth